Literature DB >> 10470676

Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima.

F Nara1, M Tanaka, S Masuda-Inoue, Y Yamasato, H Doi-Yoshioka, K Suzuki-Konagai, S Kumakura, T Ogita.   

Abstract

Scyphostatin is a specific inhibitor for mammalian neutral magnesium-dependent sphingomyelinase with a fifty percent inhibition concentration (IC50) value of 1.0 microM. When used to inhibit lysosomal acid sphingomyelinase, an approximately 50-fold greater concentration is required. In human peripheral monocytes, the compound inhibits bacterial lipopolysaccharide (LPS)-induced prostaglandin E2 production and LPS-induced interleukin-1beta production with IC50 values of 0.8 microM and 0.1 microM, respectively. In rat, p.o. administration of the compound has also been shown to inhibit carrageenin-induced paw edema. Thus, it is hoped that utility of scyphostatin as a pharmacological tool will contribute to our understanding of the role of ceramide in the cellular inflammation process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470676     DOI: 10.7164/antibiotics.52.531

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  14 in total

Review 1.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 2.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis.

Authors:  J K Chen; J Capdevila; R C Harris
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

Review 4.  Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

Authors:  Jan Skácel; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

5.  Neutral sphingomyelinase activity dependent on Mg2+ and anionic phospholipids in the intraerythrocytic malaria parasite Plasmodium falciparum.

Authors:  K Hanada; T Mitamura; M Fukasawa; P A Magistrado; T Horii; M Nishijima
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

Review 6.  Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes.

Authors:  Achraf A Shamseddine; Michael V Airola; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2014-10-27

Review 7.  Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.

Authors:  Catherine Pavoine; Françoise Pecker
Journal:  Cardiovasc Res       Date:  2009-01-28       Impact factor: 10.787

8.  Dynamic kinetic resolution during a vinylogous Payne rearrangement: a concise synthesis of the polar pharmacophoric subunit of (+)-scyphostatin.

Authors:  Thomas R Hoye; Christopher S Jeffrey; Dorian P Nelson
Journal:  Org Lett       Date:  2010-01-01       Impact factor: 6.005

9.  Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.

Authors:  Akira Sakata; Takashi Ochiai; Hiroshi Shimeno; Sadao Hikishima; Tsutomu Yokomatsu; Shiroshi Shibuya; Akihisa Toda; Reiko Eyanagi; Shinji Soeda
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

Review 10.  Novel chemotherapeutic drugs in sphingolipid cancer research.

Authors:  Daniel Canals; Yusuf A Hannun
Journal:  Handb Exp Pharmacol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.